How about MNKD? Al Mann is a multi-billionaire who is the Elon Musk/Apple Jobs of the healthcare sector. He invented the insulin pump, is about to release an ultra-fast acting insulin inhaler (compact whistle size, fits in purse, think easy to use like iPod/iPhone) which gives virtually instant control over managing glucose levels during a meal. Also working on a bionic eye.
chippy, e-mail my yahoo account if you are interested in joining a discussion group on BSD Medical. If you know the history of the company, I think you can make a valuable contribution.
bluechiptool, if you send an e-mail to my yahoo account, I can get you in on some good discussions we are having concerning the company.
Butch tried a patchwork of distributors in the US but that failed. He claimed it had to do with no minimum orders in the contracts, but I imagine there weren't enough incentives for these independent distributors to push the product (they have a number of products in their portfolio and they'll push the ones with the best incentives). As to the FPU program, distributors sell the equipment. They are not set up to schedule, track, prepare, and transport equipment from hospital to hospital. So this has to be done by BSD Medical reps. BSD piloted the program in Salt Lake City, and when they were convinced it could be done in other large cities, they rolled it out. It's not a bad idea, actually. It's a kind of marketing tool. If enough doctors start using the equipment in the hospital, then the hospital will consider buying it. But the doctors have to be aware of the program and equipment. That's why BSD is doing all these demonstrations at conferences. It's just that there's some overhead on BSD's part to get reps in these cities. They are spread so thin now and have little capital to spare with the Terumo deal at stake.
Yeah, I have practically everybody here on ignore. Reminds me of Facebook. Most of the posts are not worth reading and are just clutter.
Regarding my comment about sales slowly gaining traction, I believe there is a critical mass type of action we are seeing. There are a handful of sales now but as word gets out and a "me too" mentality sets in, there will be a burst of activity, a kind of chain reaction. It starts off with key opinion makers, followed by early adopters, then specialists, and finally mass adoption as the procedures go from a novel treatment to mainstream standard of care. And all this has to happen within budgetary cycles and as Europe emerges from austerity. Right now, we are at the key opinion makers stage, soon to be entering in the early adopters stage. That's how I see it. So Europe is promising no doubt. And I see Asia emerging with the hyperthermia sales. Let's just hope they are sustainable. I think they will be if it follows the course of Europe.
The US is a bit more problematic. I do agree that one should expect the FPU program to eventually subside as sales pick up, but I don't see a whole lot of sales from the numbers. What is most telling is that there have been no PR's of sales in the US in a while, and we know that Butch is known to crank up the PR machine on even a single sale. Indeed, Butch and Bill are either vague or evasive when you bring up the FPU numbers. My personal feeling is that FPU expansion has stalled because they need to devote their entire resources at the moment to the Terumo rollout.
Well, I work for a Fortune 50 company and we have these partnership confidentiality agreements in place all the time, so it's actually pretty typical. I don't think BSDM is saying Terumo wants to keep MWA a secret. They want to keep their SALES a secret. Believe me, the way BSDM highlights single sales in the country, they would want to do the same in Europe if they could. BSDM is definitely a PR machine, so I have to believe that there is some NDA in place. You can look at the numbers in the 10-Q (disposables and well as revenues, backing out the 2 hyperthermia sales) and conclude that Terumo sales are not stellar but are slowly gaining traction. The fact that Butch called Terumo "methodical" and that they've not gone as fast as anticipated suggests the buildout is gradually ramping, but ramping nonetheless. I'm more concerned about the FPU program stalling in the US.
Poison pill is only for hostile takeovers. I'm talking about friendly takeovers. As to Butch's involvement, he claims 7. I was able to confirm 5. How do you know how involved he was? I don't think either of us knows for sure. Did you work for him or with him? Re the $6 figure, you can study the sale of Vivant in 2005, look up inflation rates on the gov website, bring that figure up to 2014. Then figure in the hyperthermia business, which is gaining traction in Asia. I don't have the spreadsheet with me, but it comes out to around $210M.
I agree re selling the company. I believe based on past sales of similar companies, the stock is worth $6 per share. But the company needs to prove to a buyer that there is demand for their products. Hopefully, the Terumo and Asian sales will bear that out. It's a good indicator that the company will likely be sold given that one of the board members holds 6M shares, is up in age, and Butch is known to flip companies (he's been involved in 7).
Not true that all the other med device companies are doing fine. Check CRDC. Small med device companies that require use in a hospital have a tough road ahead of them. Very difficult to break into. Hospitals have consolidated and are now giant corporations run by bean counters.
My personal feeling is that BSDM should have modified the MTX-180 for applications that can be done in a doctor's office, like the Thermatrx. That was a joint venture with Oracle Strategic Partners in the 2000 timeframe that sold 300 in 3 years directly to doctor's offices for the treatment of BPH (enlarged prostate). The business was sold because the partner wanted out and BSD pocketed $30M+ from that deal. So it's been 10 years. That equipment needs to be replaced. Why not do a Thermatrx II? Generate some quick revs and plow that into expanding the FPU program and in marketing to hospitals.
No raw nerve here, my point is what do you bring to the table? There is no reason why I should share any information with you, not that I would divulge the personal info I have. You have not made yourself valuable. Brjj has, through his connections. As to you trying to rattle my cage, it's not working. I am not fazed by name calling. I am a logical, methodical engineer. I don't care if you like me or not. I do my DD and that's what I'm focused on. My opinion: I don't think BSDM's products are the greatest thing since sliced bread. I see Europe at an inflection point, Asia on the rise, and the US stalled. The latter is what I'm trying to address with management.
i don't have anything to prove to you. I needed to prove it to myself before I started collaborating with him. He introduced me to Butch in a conference call about a year and a half ago, and I've had a number of productive sessions with Butch and Bill since then. I really don't care whether you believe it or not. All that matters to me is that brjj7 is who he says he is and that he can get me into the company. He has done that and we continue to compare notes. As to you, what value are you to me?
Drdreback, all you have to do is do a property search under his family name in NYC . One could tally up the value of the property based on the property tax records if one wanted to get his family's net worth. He is legit, trust me. I have lots of corroborating evidence : name, telephone number, business name, email address,, business address etc.. But I'm not going to divulge them to you or anyone else here.
not sure why he doesn't post any more, but I do know he family owns lots of valuable commercial real estate in NYC. Wouldn't doubt his family's holdings are worth $30M.
each person must do his own due diligence. Not all dilutions are bad. Some are, in fact, strategic. What would you say if Boston Scientific took a stake in the company? This is where the company has failed. The last dilution should never have involved Roth, which is known to attract vulture capitalists.
Yes, this board has its share of cheerleaders and naysayers, for sure. And it certainly has taken the company a long time to deliver. It's that way with almost all small companies unless they are backed by venture capital. And that, unfortunately, is what BSD Medical lacks. Without VC, you have no visibility, no buzz in the marketplace. You simply have to go the tried and true route of making a profit quarter-after-quarter. For BSD Medical, it's been especially tough, because their equipment needs to be placed in a hospital, and it is very difficult to get on their radar screens. What mid-level hospital procurement agent is going to put his career on the line with a virtually unknown company? The only way they would do it is if there is sufficient demand by doctors. This is what the FPU program is all about. But is takes a long time to get off the ground and reach critical mass. Ultimately, canstic could be proven right, but it will take many years.
afrezzauser, when you do your testing, do you still require a finger #$%$? Or do you use a wireless biosensor like the Echo Symphony? Was wondering if Mannkind could build the receiver into the inhaler so that it could signal when you need another puff and what dosage to use.
Who are they going to replace him with? Who would take the job? Who would want to relocate to the backwaters of Utah? Butch is about as good a CEO as BSD Medical could hope to get. The company needs to be sold if they can't ramp sales soon. The consumables were up 32% quarter-over-quarter, so that looks promising. But they need to be ramping up much faster than they are.